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Abstract 
A series of peptides of 15 amino acids with sequences contained in human extracellular matrix (ECM) proteins (fibronectin, laminin 
A, laminin Bl, tenascin, undulin, q-chain of type IV and VIII collagen and q-chain of type VIII collagen) have been synthesized. The 
selected structures conformed to the following pattern: (i) Pro at position 6, (ii) Leu, Lys, Ile, Val, Ala or Gly at position 2, (iii) Glu or 
Asp at position 11. Fibronelctin and the indicated peptides, when present in cultures of lymphomononuclear cells from healthy donors, 
promoted stimulation of monocytes manifested by a release of IL-la, IL-lj3, IL-6 and TNFcy; an increase in the percentage of cells 
expressing CD14, CD16, CDllb and CD14/CD16; an increase in cytotoxicity against HT-29. Cytotoxicity against K562 and Daudi cells 
(targets of NK and LAK cells) was also observed together with an increase in the percentage of cells expressing CD56, CD56/CD16 
(corresponding to NK c&s), and CD56/CD8 (corresponding to NK-like lymphocytes), indicating a stimulation of lymphocytes. 
Activated monocytes and lymphocytes contained a large number of granules with DNAse activity. These results suggest that at least some 
of the immunological properties of ECM proteins could be accounted for by motifs fulfilling a characteristic sequence pattern shared by 
all of them. 
Keywords: Extracellular matrix protein; CD14+/CD16+ Monocyte; CD56 surface marker; LAK dependent cytotoxicity; TNFo; Interleukin release; 
(Human) 
1. Introduction 
Extracellular matrix @CM) proteins are known to play 
an active role in the physiology of the tissues they belong 
to. They also affect the activity of cells penetrating the 
tissues as a consequence: of migratory processes. An in- 
creasing number of reports underscore the involvement of 
ECM proteins in a variety of processes related to the 
activity of the immune system, such as activation, prolifer- 
ation, differentiation, homing and cell migration [l-3]. 
Fibronectin as well as fragments 
digestion with chymotrylpsin are 
secretion of TNF~x [4]. 
derived from it through 
known to stimulate the 
Abbreviations: ECM, extracellular matrix; Fn, fibronectin; LPS, lipo- 
polysaccharide. 
* Corresponding author. Fax: + 34 48 105649. 
The immunomodulating properties exhibited by pep- 
tides derived from Staphylococcus aureus protein A al- 
lowed us to identify a common structural pattern associ- 
ated with them: a length of at least 15 amino acid residues 
with a proline at position 6; valine, leucine, isoleucine, 
glycine, alanine or lysine at position 2; and glutamic or 
aspartic acid at position 11 [5]. Surprisingly, this pattern is 
present in a number of ECM proteins [6-131. This coinci- 
dence prompted us to explore the immunomodulating 
properties of synthetic peptides modelled after sequences 
of ECM proteins and containing those structural features. 
The results show that all these peptides stimulated human 
lymphomononuclear cells as manifested by: (i) a release of 
IL-la, IL-l/3, IL-6 and TNFa; (ii) an increase in the 
percentage of cells expressing CD14, CD16, CDllb, CD56, 
CD14/CD16, CD56/CD16 and CD56/CD8; (iii) an in- 
crease in cytotoxicity against HT-29, K562 and Daudi 
cells; and (iv) an increase in granules containing DNAse 
activity. The possibility that proteolytic fragments from 
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ECM proteins might participate as immunomodulators in 
the process of activation and maturation of monocytes and 
stimulation of lymphocytes is suggested. 
2. Materials and methods 
angle and 90” light scattering measurements were recorded. 
5000 cells were analyzed for each determination. Percent- 
age of positive cells was determined after subtraction of 
nonspecific labelling events, which, in turn, was calculated 
in each measurement with the corresponding isotype con- 
trol. 
2.1. Cell source and preparations 2.5. Cytokine determinations 
Lymphomononuclear cells were isolated (from venous 
blood drawn from healthy donors) by centrifugation over 
Ficoll-Hypaque at 2500 X g for 15 min [4]. Isolation and 
purification of monocytes was also carried out as described 
[4], allowing them to adhere for 6 h at 37°C to culture 
plates and removing nonadherent cells contained in the 
supernatant followed by three vigorous washings with 
saline solution. When indicated, the stimulated cells were 
separated in the following way: after incubating the whole 
lymphomononuclear population, monocytes were carefully 
scraped off from the surface of the culture flasks and the 
resulting cell suspension was treated with magnetizable 
polystyrene beads coated with a primary monoclonal anti- 
body specific for the CD14 membrane antigen (Dynabeads 
for monocyte separation, Dynal, Oslo, Norway). 
IL-la, IL-lp, IL-6 and TNFcx were measured by the 
quantitative ‘sandwich’ enzyme immunoassay technique 
with commercially available kits (Quantikine, R and D 
Systems). 
2.6. Cytotoxicity assay 
2.2. Cell culture conditions 
The 4 h 51Cr release cytolysis assay [16] was performed 
with K562 and Daudi cells as targets, essentially as previ- 
ously described [5]. Cytotoxicity associated with mono- 
cytes was determined using lymphomononuclear cells or 
purified monocytes as effector cells, and HT-29 cells from 
a human adenocarcinoma [17] cultured in monolayer as 
target cells. HT-29 cells were labelled with 1 &i/ml of 
L3H]thymidine when they had reached a confluence of 
50% and incubated at 37°C for 16-18 h. The incubation 
with the effector cell was carried out at 37°C and 5% CO, 
for 72 h. 
Blood lymphomononuclear cells or monocytes were 
cultured at 2. lo6 per ml in RPMI-1640 medium (Bio- 
chrom, Berlin, Germany) supplemented with 2.5% of au- 
tologous serum, 2 mM L-glutamine, penicillin (100 U/ml), 
and streptomycin (100 pg/ml) in humidified atmosphere 
with 5% CO, at 37°C. 
2.7. Extraction of granule proteins and gel electrophoresis 
2.3. Chemical synthesis of peptides 
The synthesis of the various peptides was carried out by 
the solid phase method of Merrifield [14], with the Fmoc 
modification [ 153. 
2.4. Surface markers 
Immunofluorescence studies were performed with a 
Coulter Epics flow cytometer (Coulter Electronics, Hialeah, 
FL). The monoclonal antibodies used in this study were: 
Leu-lla (CD161, Leu-M3 (CD14), Leu-19 (CD56), Leu-2a 
(CD8), obtained from Becton-Dickinson (Mountain View, 
CA) and anti-MAC1 (CDllb) from Immunotech 
(Marseille, France). Antibodies were used as conjugates of 
fluorescein isothiocyanate (FITC) or Rhodamine 6 G. Each 
assay was accompanied with its appropriate isotype con- 
trol. Aliquots containing 5 * lo5 cells were incubated at 
4°C in 50 ~1 of PBS-0.1% BSA with the monoclonal 
antibody for 30 min. After incubation the cells were 
washed twice with cold PBS/O.l% BSA. Cells were then 
fixed in 500 ~1 of formaldehyde in 2% PBS. Forward 
The isolation of secretion granules was carried out 
using a Percoll density-gradient after disrupting the cells 
with a nitrogen bomb [18]. Granule proteins were extracted 
following the procedure used by Podack et al. [19] as a 
preliminary step in the purification of perforin 1 from 
cytolytic T-cell granules. Isolated granules were mixed 
with an equal volume of 1 M NaKHPO, buffer (pH 7.4), 
containing 10 mM benzamidine-HCl, 1 mM EDTA and 3 
mM NaN,. After the addition of a small volume of a 
concentrated solution of phenylmethylsulfonyl fluoride in 
methanol to give a final concentration of 2 mM, the 
mixture was allowed to stand on ice for 30 min. The white 
precipitate of Percoll was removed by centrifugation at 
30 000 X g for 30 min; the supematant was dialyzed against 
10 mM NaKHPO, buffer (pH 7.4), 1 mM EDTA and 3 
mM NaN,. Protein electrophoresis was carried out follow- 
ing the technique of Laemmli and Favre [20]. The protein 
mixture ‘Dalton Mark III L’ (Sigma, Saint Louis, MO) 
was used as reference for the estimation of molecular 
mass. 
2.8. Detection of DNAse activity 
The detection of DNAse activity in the protein extract 
was carried out by its ability to degrade genomic DNA. 
Approx. 50 pug of the extracted granule proteins were 
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incubated with 10 pg of protein-free DNA at 37°C for 24 
h in 100 ~1 of a 50 mh4 NaCl, 10 mM MgCl,, 1 mM 
dithiothreitol, 10 mM Tris HCl-buffer (pH 7.9). An aliquot 
of 50 ~1 of the resulting mixture was applied to a 1% 
agarose gel, and subjected to electrophoresis at a voltage 
of 70 V in 1 mM EDTA, 40 mM Tris-HCl buffer (pH 7.51, 
containing 0.5 pg per ml of ethidium bromide. Genomic 
DNA was obtained from human blood as described in the 
literature [21]. 
3. Results and discussiom 
3.1. Sequences of active peptides 
The amino acid sequence of different proteins from 
extracellular matrix is already well known [6-131. Peptides 
fulfilling the structural requirements described as needed 
for immunomodulating a.ctivity [5] and consisting of 15 
amino acids (14 of them encompassing sequences present 
in fibronectin [6], laminin A [7], laminin Bl [8], a,-chain 
of type IV collagen [9], tenascin [ 101, undulin [ll], cr,-chain 
of type VIII collagen [12] and &,-chain of type VIII 
collagen [13]) were synthesized. The extra amino acid 
residue, always on the carboxyl end, was valine, added for 
synthesis convenience. Table 1 shows the sequence of 
synthetic peptides capable of inducing cytotoxicity against 
tumour cell lines HT-29, K562 or Daudi, when lym- 
phomononuclear cells were incubated in the presence of 
any of them, for 7 days. Table 2 shows the cytotoxicity 
against HT-29 cells induced by Fn or peptides derived 
from this or other ECM proteins on lymphomononuclear 
cells or purified monocytes. Peptide NVLGAPKKL 
NESQAV (Pa) and IFNy were used as positive controls, 
and peptide ADAQQNKFNKDQQS (PC) as negative con- 
trol [5]. A maximum value for the cytotoxicity induced on 
isolated monocytes was observed at a 2:l effector to target 
cell ratio, whereas cytotoxicity induced on lym- 
phomononuclear cells increased with an increase of the 
effector to target cell ratio (from 2:l to 2O:l). A potent 
enhancement of both monocyte and macrophage tumour 
cell cytotoxicity elicited by Fn has already been reported 
[22]. Fig. 1 shows the dose-dependent cytotoxicity against 
K562 and Daudi cells induced by Fn or peptides derived 
from ECM proteins. Pa was used as positive control, and 
PC as negative control. A maximum value of cytotoxicity 
K562 
P2 P3 P6 P7 PI0 PI1 PI2 PI8 PI9 Pa n c PFM 
P2 P6 P7 PI0 
DAUDI 
cl 10 %I 
P12 PI8 PI9 Pa En PC PFM 
Fig. 1. Cytotoxicity induced by synthetic peptides derived from EMC proteins on lymphomononuclear cells. Cytotoxicity was determined after 7 days of 
incubation. Results are expressed as percentage of ” Cr release using K562 (top) or Daudi (bottom) cells as target. Effector to target ratio was 5O:l. The 
results are representative of cells obtained from 10 different healthy donors. See Table 1 for peptide identification. PFM, peptide-free medium. 
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induced by any of the active peptides included in Table 1 
was reached with 30 pg per ml. In the case of Fn the 
cytotoxicity was higher at 40 than at 30 pg, a result 
consistent with the much higher molecular mass of Fn. The 
cytotoxicity induced by active peptides was also found to 
be time-dependent when measured in the interval from 1 to 
7 days; after a slow increase in the first 3 days of 
incubation a sharp increase in cytotoxicity was observed 
between days 3 and 5 to level off between days 5 and 7 
(data not shown). 
3.2. Surface markers of lyrnphomononuclear cells after 
incubation in the presence of active peptides 1 
Surface markers in the cell populations after incubation 
in the presence of active peptides or fibronectin were also 
studied. Table 3 shows the results obtained together with 
those corresponding to peptide Pa and PC used as positive 
and negative controls respectively. The proportion of cells 
expressing markers CDllb (NK, monocytes and activated 
macrophages), CD14 (monocytes and macrophages), CD16 
(macrophages, monocytes and NK), and CD56 (NK and 
activated lymphocytes) was elevated in cell populations 
incubated in the presence of active peptides or fibronectin 
with respect to those incubated in the absence of peptides 
or incubated in the presence of negative control PC. The 
percentage of cells expressing these markers remained 
unaltered in populations incubated in the absence of pep- 
tides or in the presence of PC. The induction of these 
markers caused by any of the active peptides was found to 
Table 1 
Sequences of synthetic peptides, derived from extracellular matrix pro- 
teins, active as inducers of cytotoxicity on human lymphomononuclear 
cells 
Product tested Peptide sequence a Protein Position b 
Pl KLGVRPSQGGEAPR Fibronectin 1088-1101 
P2 IKGLKPGVVYEGQL Fibronectin 639-652 
P3 IISCHPVGTDEEPL Fibronectin 2015-2028 
P4 QIGHIPREDVDYHL Fibronectin 1967-1980 
P5 LVRYSPVKNEEDVA Fibronectin 1271-1284 
P6 LKERNPEGCSECFC Laminin A 475-488 
P7 VVRLVPENFRDFNT Laminin A 620-634 
P8 MLRESPGGMREKGR Laminin A 1981-1993 
P9 TKVSHPALLSDGKW Laminin A 2770-2783 
PlO GISTGPMKKVDDII Laminin Bl 155-168 
Pll QALASPGSCLDEFR or Collagen IV 1569-1582 
P12 IGNLKPDTEYEVSL Tenascin 430-443 
P13 RIKYAPISGGDHAE Tenascin 494-507 
P14 LLWKTPLAKFDRYR Tenascin 573-586 
P15 QGYRTPVLSAEAST Tenascin 719-732 
P16 RGYRTPVLSAEAST Tenascin 992-1005 
P17 RVTWHPLSADEGLH Undulin 454-467 
P18 GKEAVPKKGKEIPL a1 Collagen VIII 100-113 
P19 AGLHLPNGGVEGAV oz Collagen VIII 484-497 
a An extra valine residue, not shown, was added in the C-terminus for 
synthesis convenience. 
b Numbering of the amino acid residues at the corresponding protein. 
Table 2 
Cytotoxicity induced by synthetic peptides derived from ECM proteins on 
lymphomononuclear cells or monocytes against HT-29 cells 
Product tested Monocyte Lymphomononuclear 
cells 
None 26 27 
PC 26 28 
Pa 60 67 
Fn 50 51 
Pl 51 57 
P2 56 63 
P3 70 67 
P4 62 62 
P5 62 63 
P6 51 62 
P7 53 60 
P8 46 51 
P9 44 48 
PlO 54 62 
Pll 68 68 
P12 56 64 
P13 61 60 
P14 42 45 
P15 41 43 
P16 47 59 
P17 56 60 
P18 52 60 
P19 50 53 
IFNy 73 70 
Peptide concentration was 30 pg/106 cells and that of Fn 40 pg/106 
cells. IFN-y, at a concentration of 100 U/lo6 cells, was used as reference 
control. Cytotoxicity was determined after 7 days of incubation and 
expressed as % of [3H]thymidine released. Results are representative of 
cells obtained from five different donors and correspond to the mean of 
the values of two replicate wells. Standard deviations were < 10%. 
Effector to target cell ratio was 2:l when using isolated monocytes and 
2O:l with the whole population of lymphomononuclear cells. 
be time-dependent (data not shown): the percentage of 
cells expressing CD14 and CD16 reached values close to 
its maximum after the second day of incubation; however, 
in the case of CDllb and CD56 no change in the percent- 
age of cells expressing them was observed until past 48 h. 
The existence of a subset of monocytes coexpressing 
CD14 and CD16 antigens (lo-15% of all monocytes), 
differing in some features from monocytes with a high 
expression of CD14 [23,24], prompted us to explore the 
possibility that this precise group could be affected by the 
active peptides. In a different set of experiments the per- 
centage of cells expressing both CD14 and CD16 surface 
markers has been determined after incubating lym- 
phomononuclear cells in the presence of active peptides or 
Fn for 7 days. The proportion of cells expressing both 
markers was double in the case of Fn, triple in the case of 
P6 and quadruple in the presence of either P3 or Pll, with 
respect to cells incubated in the absence of peptides. No 
change in that proportion was observed when the incuba- 
tion was carried out in the presence of PC or IL-2 (500 U 
per lo6 cells). 
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Table 3 
Phenotypes of lymphomononuckear cells after peptide activation 
Product tested Cells expressing surface markers (%) 
CDllb CD14 CD16 CD56 
None 6 5 5 4 
PC 6 5 6 5 
Pa 18 16 16 20 
Pl 15 13 12 13 
P2 15 17 20 15 
P3 16 17 20 19 
P4 10 13 14 14 
P5 17 16 17 16 
~6 15 15 16 20 
~8 10 12 14 16 
PlO 16 16 16 17 
Pll 19 17 19 19 
P13 12 15 16 14 
P14 10 12 15 16 
P16 14 16 17 13 
P17 14 15 20 17 
Fn 10 11 13 13 
IL-2 5 4 11 22 
Results are representative of lymphomononuclear cells obtained from six 
different donors and processed independently and determined in duplicate 
after 7 days of incubation. Stalndard deviations were < 10%. Peptides 
were used at a concentration of 30 pg/106 cells, Fn at 40 pg/106 cells 
and IL-2 at 500 U./lo6 cells. 
The elevation of CD14/CD16 induced by the active 
peptides may reflect a differentiation and maturation of 
monocytes. As strongly suggested by Ziegler-Heitbrock et 
al. [25], these CD14+/CD16+ monocytes are more differ- 
entiated than CD14++ monocytes, are efficient as antigen 
presenting cells, have a higher tendency to migrate to the 
tissues, and may be considered as circulating macrophages. 
Table 4 
Cytokine release by lymphomononuclear cells after peptide activation 
The increase in CDllb (alpha chain of CR31, a marker 
related to phagocytosis [26], suggests that ECM proteins or 
peptides derived from them may also play a role in the 
activation of the phagocytic machinery. 
The simultaneous expression of CD16 and CD56 or 
CD8 and CD56 surface markers has also been studied in 
lymphomononuclear cells incubated in the presence of 
some of the active peptides. The increase in the percentage 
of cells expressing CD56 (Table 3) could be specifically 
ascribed to NK or activated lymphocytes. NK 
(CD16/CD56) represent approx. 60% and activated lym- 
phocytes (CD8/CD56) 40% of the whole population of 
cells expressing CD56 surface markers (data not shown). 
These results suggest that peptides derived from ECM 
proteins induced not only a stimulation of monocytes, but 
also an activation of lymphocytes. 
3.3. Cytokine release 
In order to ascertain the possible stimulation of mono- 
cytes, cytokines IL-l (Y, IL-lp and TNFa! were deter- 
mined in the supernatants after the incubation of lym- 
phomononuclear cells in the presence of peptides. The 
results collected in Table 4 clearly show that these cy- 
tokines were in fact released by the activated cells. LPS 
and active peptide Pa were used as positive controls. The 
nature of the TNFu released was confirmed with anti-TNFcz 
antibody. It should be noticed that peptides P3 and Pll 
were also the most active as regards to the production of 
these cytokines. The concentration of IL-lp and TNFcr in 
the supernatant was higher after 24 h than after 48 h, 
whereas that of IL-10 was slightly lower at 24 h than at 
48 h. It has been described that a 120 kDa fragment of Fn 
Product tested 
PC 
Pa 
Pl 
P2 
P3 
P4 
P5 
P6 
P8 
PlO 
Pll 
P13 
P14 
P16 
P17 
Fn 
LPS 
IL-1 a @g/106 cells) IL-1P (ng/106 cells) TNFa (U/lo6 cells) 
24h 48 h 168 h 24 h 48 h 168 h 24 h 48 h 168 h 
20 25 7 1.1 1.3 0.5 50 50 15 
18 25 8 0.8 1.2 0.3 40 45 10 
95 105 30 2.7 1.8 0.6 210 160 40 
76 84 60 1.7 1.4 0.4 180 160 30 
74 79 70 2.1 1.6 0.5 120 110 80 
100 120 45 2.7 2.1 0.4 280 180 60 
95 97 40 2.2 1.7 0.6 270 120 50 
65 80 50 1.7 1.4 0.6 220 110 60 
94 98 55 2.1 2.3 0.5 230 190 40 
63 78 30 1.8 1.9 0.5 210 170 30 
88 95 35 1.9 2.1 0.6 240 160 50 
85 100 35 2.8 2.5 0.5 240 180 40 
83 85 37 1.4 1.7 0.4 210 160 35 
65 80 35 1.9 2.2 0.5 190 150 45 
75 80 35 1.7 2.0 0.4 200 160 80 
65 82 15 2.2 2.4 0.3 220 170 50 
55 65 10 2.7 2.8 0.6 200 150 80 
180 185 150 3.5 3.0 1.2 380 330 170 
Results are representative of cells obtained from seven different donors and are the mean of the values obtained in two replicate wells. Standard deviations 
were < 10%. Peptide concentration was always 30 Kg/lo6 cells. Fn, 40 pg/106 cells; LPS, 10 pg /lo6 cells. 
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provokes a stimulation of monocytes accompanied by se- 
cretion of TNFcz [4]. 
Cytokine release took also place when isolated mono- 
cytes were incubated for 24 h in the presence of Pa, P3 or 
Pll (data not shown); the values were similar to those 
obtained with LPS, and more than double than those 
obtained with inactive control PC. 
IL-6 was determined in the supernatants of lym- 
phomononuclear cells incubated in the presence of active 
peptides. In the presence of negative control PC no signifi- 
cant release of IL-6 took place. Active peptides tested (Pa 
and P3) provoked a release of IL-6 (approx. 400 pg per 
lo6 cells suspended in 1 ml) after 4 h of incubation. After 
6 h, values of up to 1200 pg per lo6 were observed. 
Determinations carried out past 6 h and up to 10 days gave 
similar values. 
3.4. Increase in DNAse activity associated to secretion 
granules of activated lymphomononuclear cells 
Experiments were carried out in order to detect DNAse 
activity in the protein extracts from granules present in 
cells stimulated with some of the active peptides. The 
granules were obtained both from the entire incubated 
population of lymphomononuclear cells as well as from 
monocytes or lymphocytes isolated from it, after an incu- 
bation period of 7 days. The layer corresponding to the 
granules in the centrifugation gradient was clearly visible 
if the incubation had been carried out in the presence of 
active peptides, and almost imperceptible in the case of an 
1 2 3 4 kDa 
36 
29 
24 
Fig. 2. SDS-PAGE of protein extracts from secretion granules obtained 
from lympbomononuclear cells incubated for 7 days in the presence of 
inactive peptide PC (Lane 11, active peptide Pa (Lane 21, peptide P3, 
derived from fibronectin (Lane 3), and peptide Pll, derived from or 
collagen IV (Lane 4). 
A ’ 234 5 
Fig. 3. Electrophoregram reflecting DNAse activity of protein extracts 
from secretion granules of lymphomononuclear cells incubated for 7 days 
under different conditions. Cells were carefully scraped off from culture 
flasks for further processing. (A) Activity present in monocytes isolated 
by means of magnetizable beads coated with CD14 antibody after incuba- 
tion of lymphomononuclear cells in the absence of activators (lane 11, in 
the presence of control active peptide Pa (lane 21, peptide 3 (lane 31, 
control peptide PC (lane 4). Protein-free human genomic DNA (lane 5). 
(B) DNAse activity present in granules obtained from cells remaining 
after the removal of monocytes. Cells had been previously incubated in 
the presence of inactive control PC (lane 11, and P3 (lane 2) 
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incubation with control peptide PC, when using an equal 
number of cells. This is a clear indication that granule 
formation is part of the activation process. Fig. 2 shows a 
representative polyacrylamide gel electrophoregram of pro- 
tein extracts from secretion granules belonging to an equal 
number of lymphomononuclear cells (10’ cells) incubated 
with PC, Pa, P3 or Pll for 7 days. The electrophoregram 
reflects the increase in granule proteins after incubation in 
the presence of active pe:ptides, with no apparent relative 
increase in any of the observed bands. The most prominent 
band in all the lanes corresponded to a 45 kDa component. 
A total of lo8 lymphomononuclear cells (2 . lo6 cells 
per ml) were incubated in the presence or absence of 
active peptides Pa, P3, IPll, fibronectin or the inactive 
control peptide PC; after the incubation the cells which had 
adhered were scraped off and resuspended in the medium; 
monocytes were then isolated by means of CD16antibody 
coated magnetizable beads. Nuclease activity was assayed 
by electrophoresis on an agarose gel after incubation of 
genomic DNA together with the extracted granule proteins 
for 24 h. Hydrolytic activity was detected in the extracts 
from granules obtained from the whole lymphomononu- 
clear population incubated in the presence of Fn or the 
active peptides Pa, P3 and Pll as well as from monocytes 
isolated after the incubation of lymphomononuclear cells. 
The electrophoregram of Fig. 3A clearly shows the frag- 
mentation of genomic DNA caused by the protein extract 
corresponding to granules belonging to monocytes isolated 
from lymphomononuclear cells incubated in the presence 
of Pa or P3 (lanes 2 and 3). The granules obtained from 
monocytes isolated frorn an equal number of lym- 
phomononuclear cells incubated in the absence of active 
peptides or in the presence of the negative control PC 
exhibited no or very limited DNAse activity (lanes 1 and 
4). Fig. 3A shows also that spontaneous hydrolysis of 
DNA could be disregarded, since genomic DNA not ex- 
posed to cell extracts was left completely unaffected (lane 
5). Fig. 3B shows that DNAse activity was also present in 
granules extracted from cells remaining after the removal 
of monocytes from the whole lymphomononuclear popula- 
tion incubated in the pre:sence of P3 (lane 21, but not if 
they had been incubated in the presence of PC (lane 1). 
Differences in digestion pattern between monocyte and 
non-monocyte granules could be due to different nucle- 
ases. The DNAse activity now reported could be associ- 
ated to the 45 kDa component; this possibility is suggested 
after the description by otlhers of the existence of cytotoxic 
components with nucleasie activity and similar molecular 
mass produced by macrophages activated with lipopoly- 
saccharide or ionophore A23187 [27] and by cytotoxic T 
lymphocytes [28]. 
In conclusion, we have found that effects induced by Fn 
on the immune system, such as an enhancement of tumori- 
tidal activity [22], or the secretion of TNFar by human 
monocytes ascribed to a large fragment of Fn [4], can also 
be obtained with small synthetic peptides containing se- 
quences present in fibronectin or other ECM proteins and 
fulfilling a well defined structural pattern. Furthermore, 
these active peptides have other effects, such as an in- 
crease in NK and LAK activity as well as a differentiation 
and activation of monocytes, not previously described for 
ECM proteins or peptides derived from them. In view of 
the potential of these peptides to stimulate the immune 
system it could be suggested that: (i) proteolytic fragments 
derived from circulating Fn may play a key role in the 
differentiation and activation of blood monocytes and lym- 
phocytes; thus the proteolytic and autoproteolytic proper- 
ties of Fn [29-321 could link this protein to the modulation 
of the immune system. In this respect it is interesting to 
note that fibronectin has several functional domains joined 
by flexible peptide segments highly sensitive to pro- 
teinases [33]; and furthermore, that the five sequences 
present in fibronectin with the ‘2-6-11’ motif associated 
with immnunomodulation are contained within regions of 
the molecule marked by areas sensitive to proteinases 
[6].(ii) Peptides derived by in situ proteolysis of ECM 
proteins may be critical in the differentiation or activation 
of tissue macrophages and infiltrating lymphocytes under 
conditions such as an infection or the development of a 
tumour, in which proteolytic processes seem to increase. 
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